

Can Fin Homes logged a satisfactory quarter in terms of disbursements, asset quality, and profitability, while AUM growth was slightly softer. 1QFY27 AUM stood at Rs429.6bn, growing 11% yoy, while prepayment remained elevated at ~17.6%, thus weighing on growth. Overall asset quality was stable (marginal uptick due to seasonality); the management expects credit costs to remain contained at ~10bps. Margins (NIMs) are expected to uphold at 3.75–3.80%, supported by stable COFs and optimizing asset mix driven by a strategic shift toward high-yielding SENP and non-housing loans. Cost-to-income is expected to remain elevated (~19.5%) due to ongoing IT transformation, and normalize to ~18% after a full system rollout. Overall, 1Q is a steady quarter, with AUM growth set to reach ~14% in FY27E, as prepayment moderates and disbursements pick up. We maintain ADD on Can Fin with unchanged Jun-27E TP of Rs1,000 (implying FY28E PBV of 1.6x).

#### Strong disbursement and profitability, while growth remains soft

Can Fin posted a steady 1QFY27, with disbursements up 29% yoy (Rs26.1bn) and PAT growing 20% yoy to Rs2.7bn; AUM growth was muted at 11% yoy (Rs429.6bn) due to elevated prepayments. Reported NIM declined by ~26bps to 3.81%, largely driven by portfolio reset (from annual to quarterly); COF was stable at 6.98%. Cost-to-income rose to 19.5% (from 18.3% a year ago), on continued IT-transformation spends, though credit cost was contained at ~12bps. Asset quality was firm, with 0.87% GNPA (down by ~11bps yoy) and 0.42% net NPA (down by ~12bps yoy). The book mix continued shifting toward the higher-yielding SENP, now 32% of AUM and non-housing AUM share of ~17%.

#### Remains confident of delivering on guidance

Management remains confident of accelerating AUM growth toward its 14% target for FY27, as the strategic pivot to the higher-yielding SENP segment continues to gain traction, while indicating that elevated prepayment rates are still a key monitorable. The mgmt also indicated it targets achieving NIM of 3.75–3.80% and cost of funds to be broadly stable following the recent liability-management initiatives; any marginal yield expansion would be mainly driven by this evolving asset mix. The mgmt also stated it is progressing well on its IT transformation and core system upgrades, which would be rolled out across all branches by Sep-26, without causing any material disruption to the business. This is likely to normalize cost-to-income back to ~18% in the medium term, while credit costs are likely to be contained at ~10bps, supported by stringent underwriting standards; overall, the company targets steady-state ROA of ~2.4% and ROE of ~18% for FY27.

#### Estimates largely unchanged; maintain ADD

Considering the 1QFY27 developments and management commentary, we retain our FY27-29 estimates. We maintain ADD with unchanged Jun-27E TP of Rs1,000, implying FY28E PBV of 1.6x. Going forward, we expect AUM growth to improve, toward the ~14–15% target, as prepayments moderate and owing to healthy disbursements. ROA and ROE are expected to remain healthy, supported by a successful rollout of the company's IT transformation and strong asset quality, along with contained credit cost.

#### Can Fin Homes: Financial Snapshot (Standalone)

| Y/E 2026 (Rs mn)     | FY25  | FY26   | FY27E  | FY28E  | FY29E  |
|----------------------|-------|--------|--------|--------|--------|
| Net profits          | 8,572 | 10,858 | 11,059 | 12,506 | 14,489 |
| AUM growth (%)       | 8.3   | 10.4   | 14.9   | 15.4   | 15.8   |
| NII growth (%)       | 7.6   | 18.9   | 8.6    | 13.3   | 15.6   |
| NIMs (%)             | 3.7   | 4.0    | 3.9    | 3.8    | 3.8    |
| PPOP growth (%)      | 7.2   | 16.5   | 7.0    | 13.8   | 16.1   |
| Adj. EPS (Rs)        | 64.7  | 81.5   | 83.0   | 93.9   | 108.8  |
| Adj. EPS growth (%)  | 14.8  | 26.0   | 1.9    | 13.1   | 15.9   |
| Adj. BV (INR)        | 380.6 | 449.1  | 519.7  | 613.6  | 722.4  |
| Adj. BVPS growth (%) | 16.7  | 18.0   | 15.7   | 18.1   | 17.7   |
| RoA (%)              | 2.2   | 2.5    | 2.3    | 2.3    | 2.3    |
| RoE (%)              | 18.2  | 19.7   | 17.1   | 16.6   | 16.3   |
| P/E (x)              | 13.2  | 10.5   | 10.3   | 9.1    | 7.9    |
| P/ABV (x)            | 2.3   | 1.9    | 1.6    | 1.4    | 1.2    |

Source: Company, Emkay Research

|                       |        |
|-----------------------|--------|
| Target Price – 12M    | Jun-27 |
| Change in TP (%)      | NA     |
| Current Reco.         | ADD    |
| Previous Reco.        | ADD    |
| Upside/(Downside) (%) | 16.7   |

| Stock Data              | CANF IN  |
|-------------------------|----------|
| 52-week High (Rs)       | 972      |
| 52-week Low (Rs)        | 709      |
| Shares outstanding (mn) | 133.2    |
| Market-cap (Rs bn)      | 114      |
| Market-cap (USD mn)     | 1,183    |
| Net-debt, FY27E (Rs mn) | NA       |
| ADTV-3M (mn shares)     | 0.2      |
| ADTV-3M (Rs mn)         | 224.5    |
| ADTV-3M (USD mn)        | 2.3      |
| Free float (%)          | 0.0      |
| Nifty-50                | 24,238.5 |
| INR/USD                 | 96.5     |


#### Shareholding, Jun-26

|               |           |
|---------------|-----------|
| Promoters (%) | 30.0      |
| FPIs/MFs (%)  | 13.2/24.5 |

#### Price Performance

| (%)           | 1M    | 3M    | 12M |
|---------------|-------|-------|-----|
| Absolute      | (3.2) | (1.5) | 4.9 |
| Rel. to Nifty | (4.1) | (1.0) | 8.1 |

#### 1-Year share price trend (Rs)



#### Avinash Singh

avinash.singh@emkayglobal.com  
+91-22-66121327

#### Kishan Rungta

kishan.rungta@emkayglobal.com  
+91-22-66242490

**Exhibit 1: Quarterly earnings snapshot**

| Can Fin Homes – Quarterly Earnings | 4QFY25         | 1QFY26         | 2QFY26         | 3QFY26         | 4QFY26         | 1QFY27         | yoy          | qoq           |
|------------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|--------------|---------------|
| Interest Income                    | 9,829          | 10,111         | 10,432         | 10,631         | 10,565         | 10,870         | 7.5%         | 2.9%          |
| Interest Expenses                  | 6,343          | 6,483          | 6,386          | 6,422          | 6,342          | 6,595          | 1.7%         | 4.0%          |
| <b>Net Interest Income</b>         | <b>3,485</b>   | <b>3,628</b>   | <b>4,046</b>   | <b>4,210</b>   | <b>4,223</b>   | <b>4,276</b>   | <b>17.9%</b> | <b>1.2%</b>   |
| Other Income                       | 168            | 93             | 63             | 100            | 187            | 93             | -0.5%        | -50.4%        |
| Income                             | 3,653          | 3,721          | 4,109          | 4,310          | 4,411          | 4,369          | 17.4%        | -1.0%         |
| Operating Expenses                 | 707            | 682            | 762            | 799            | 875            | 853            | 25.0%        | -2.5%         |
| <b>Operating Profit</b>            | <b>2,946</b>   | <b>3,039</b>   | <b>3,346</b>   | <b>3,511</b>   | <b>3,535</b>   | <b>3,516</b>   | <b>15.7%</b> | <b>-0.6%</b>  |
| Provisions                         | 154            | 263            | 31             | 97             | 6              | 131            | -50.2%       | 2216.6%       |
| Credit cost (on avg. AUM)          | 0.16%          | 0.27%          | 0.03%          | 0.10%          | 0.01%          | 0.12%          | -15bps       | 12bps         |
| <b>PBT</b>                         | <b>2,792</b>   | <b>2,776</b>   | <b>3,316</b>   | <b>3,414</b>   | <b>3,530</b>   | <b>3,385</b>   | <b>21.9%</b> | <b>-4.1%</b>  |
| Tax                                | 452            | 538            | 801            | 766            | 73             | 707            | 31.5%        | 866.9%        |
| <b>Reported PAT</b>                | <b>2,339</b>   | <b>2,239</b>   | <b>2,514</b>   | <b>2,648</b>   | <b>3,457</b>   | <b>2,678</b>   | <b>19.6%</b> | <b>-22.5%</b> |
| <b>AUM</b>                         | <b>382,170</b> | <b>387,730</b> | <b>396,570</b> | <b>406,930</b> | <b>422,090</b> | <b>429,610</b> | <b>10.8%</b> | <b>1.8%</b>   |
| <b>Disbursements</b>               | <b>24,550</b>  | <b>20,150</b>  | <b>25,450</b>  | <b>27,270</b>  | <b>32,460</b>  | <b>26,090</b>  | <b>29.5%</b> | <b>-19.6%</b> |
| GS3                                | 0.87%          | 0.97%          | 0.94%          | 0.92%          | 0.85%          | 0.88%          | -10bps       | 3bps          |
| NS3                                | 0.46%          | 0.54%          | 0.48%          | 0.49%          | 0.35%          | 0.42%          | -12bps       | 7bps          |
| PCR                                | 47.75%         | 45.24%         | 48.79%         | 46.92%         | 58.82%         | 47.61%         | 237bps       | -1122bps      |
| ROA                                | 2.59%          | 2.19%          | 2.46%          | 2.55%          | 3.29%          | 2.39%          | 20bps        | -90bps        |
| ROE                                | 18.47%         | 16.93%         | 18.41%         | 18.80%         | 23.12%         | 17.15%         | 22bps        | -597bps       |

Source: Company, Emkay Research

**Exhibit 2: Valuation metrics**


|        |            |        | PBV (x) |       |       | PER (x) |       |       | ROA (%) |       |       | ROE (%) |       |       | Book Value (Rs/sh) |       |       | EPS (Rs) |       |       |
|--------|------------|--------|---------|-------|-------|---------|-------|-------|---------|-------|-------|---------|-------|-------|--------------------|-------|-------|----------|-------|-------|
|        | Price (Rs) | Upside | FY27E   | FY28E | FY29E | FY27E   | FY28E | FY29E | FY27E   | FY28E | FY29E | FY27E   | FY28E | FY29E | FY27E              | FY28E | FY29E | FY27E    | FY28E | FY29E |
| At CMP | 857        | 17%    | 1.65    | 1.4   | 1.2   | 10.3    | 9.1   | 7.9   | 2.33    | 2.29  | 2.29  | 17.1    | 16.6  | 16.3  | 519.7              | 613.6 | 722.4 | 83.0     | 93.9  | 108.8 |
| AT TP  | 1,000      |        | 1.9     | 1.6   | 1.4   | 12.0    | 10.6  | 9.2   |         |       |       |         |       |       |                    |       |       |          |       |       |

Source: Company, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)


## Results in charts

**Exhibit 3: AUM grew ~11% yoy despite elevated repayment**




Source: Company, Emkay Research

**Exhibit 4: Disbursement grew ~29% yoy, exceeding the management's stated target of Rs25bn**




Source: Company, Emkay Research

**Exhibit 5: Reported yields stood at 9.81%, declining by ~26bps on account of the portfolio transitioning from the annual to a quarterly reset**




Source: Company, Emkay Research

**Exhibit 6: Reported NIM came in at 3.81%, in line with management guidance of ~3.75%**




Source: Company, Emkay Research

**Exhibit 7: Opex ratio is range-bound**




Source: Company, Emkay Research

**Exhibit 8: Credit cost remains benign**




Source: Company, Emkay Research

This report is intended for Team White Marquee Solutions (team.emkay@whitemarquesolutions)

**Exhibit 9: Marginal increase in GNPA due to seasonality**


Source: Company, Emkay Research

**Exhibit 10: Profitability remains healthy**


Source: Company, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)


## Story in charts

**Exhibit 11: AUM CAGR expected at ~15% over FY27-29E**



Source: Company, Emkay Research

**Exhibit 12: Disbursement expected to pick up**



Source: Company, Emkay Research

**Exhibit 13: Stable yields and cost of borrowing**



Source: Company, Emkay Research

**Exhibit 14: NIM to remain in the ~3.75-3.8% range**


Source: Company, Emkay Research

**Exhibit 15: Margin uptick in opex on account of continued IT spend and infrastructure building**



Source: Company, Emkay Research

**Exhibit 16: Benign credit cost**


Source: Company, Emkay Research


This report is intended for Team White Marquee Solutions (team.emkay@whitemarquesolutions)

Exhibit 17: Broadly stable asset quality



Source: Company, Emkay Research

Exhibit 18: Healthy profitability metrics



Source: Company, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com)

## Earnings call highlights

- 1Q disbursements reached ~Rs26.1bn against a projected ~Rs25bn, delivering 29% yoy growth supported by positive traction across all 6 zones. The salaried and self-employed (SENP) segments grew 21% and 44% yoy, while the housing and non-housing portfolios expanded 28% and 32% yoy, respectively. Overall growth was further supported by positive contributions from the sales team and new branches opened post Mar-23.
- The overall portfolio rundown was elevated at Rs18.57bn compared to 4Q, primarily driven by higher part-prepayments and amortization (Rs10.72bn). Balance transfers (BT Out) were relatively stable at Rs4.08bn (vs Rs4bn in 4QFY26). The management attributed this accelerated principal repayment to the recent shift from annual to quarterly rate reset, where EMIs remained constant but tenures crashed.
- The management indicated that the interest rate gap compared to banks and larger players has widened. Previously, the company's best rate of 8.95% versus the 8.4% for competitors created a manageable differential of ~55bps. However, following the recent rate cuts, competitors have lowered their rates to 7.15-7.25%, while the company reduced its best rate to 8.4%, expanding the gap to over 100bps. This wider differential makes customer retention more challenging and contributes to the elevated prepayment pressures.
- Delinquencies across Stage 2 and Stage 3 assets declined in absolute terms compared to Mar-26, with only a marginal NPA increase of Rs170-180mn, which remains well below the historical 1Q trends.
- To offset the rising incremental borrowing costs (incremental borrowing at ~7.25% for the recently raised term loan), the company recalibrated its risk profile by increasing the threshold for special rates, from Rs2mn to Rs2.5mn. Additionally, the management indicated that 82% of its loans have a CIBIL score of above 700 currently.
- Borrowing costs were successfully optimized to 6.98% through timely commercial paper issuance and the repayment of high-cost NCDs. This proactive liability management has allowed the company to maintain a yield of 9.81%, spread of 2.83%, and NIM of 3.81%.
- The management indicated that all else being equal, the yield for a self-employed (SENP) customer is approximately 50bps higher than that of a salaried housing customer. Further, the management highlighted that while gross NPA for the salaried segment stands at ~0.60-0.63%, the SENP segment has a relatively higher NPA ratio of ~1.45-1.50%. However, even after factoring in the higher credit costs, this ~50bps yield differential makes the SENP segment margin-accretive.
- Management also highlighted that unlike other affordable housing finance companies that rely on assessed or surrogate income, Can Fin's SENP customers possess fully documented income profiles. The management indicated that the company strictly underwrites such customers based on 2-3 years of IT returns, which are independently verified through the IT portal, making its SENP segment structurally safer and of higher credit quality compared to industry peers.
- The management also clarified that the IT sector constitutes only 6% of its customer base and has seen no material impact on asset quality from the recent job losses in the sector.
- The company successfully piloted its new LOS, LMS, and core systems across five branches in Jul-26, without any business disruption and plans to implement it across the remaining 245 branches by Sep-26. Due to capitalization of this transformation, cost-to-income expected to hover at ~19.5% in the current year before normalizing back to ~18% over the next three years.
- The company expanded its Approved Project Finance (APF) portfolio by adding 60 new projects, bringing the total to 331. To maintain strict risk mitigation, the management emphasized that it caps its exposure at a maximum 10% per project.
- The company reiterated that it does not engage in developer or builder finance. Consequently, for new project tie-ups, first right of refusal for home loans typically remains with the lender that provided the project finance.

**■ Guidance for FY27**

- AUM growth target maintained at 14% for the full year, with full-year disbursements targeted at Rs130bn and 2Q disbursement target of Rs30bn
- NIM to be maintained at ~3.75-3.8%
- Cost-to-income to remain at ~19.5%
- Credit cost guidance is steady at ~10bps
- ROA and ROE aspirations: ~2.4% and ~18%, respectively

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)



Can Fin Homes: Standalone Financials and Valuations

| Profit & Loss              |        |        |        |        |        |
|----------------------------|--------|--------|--------|--------|--------|
| Y/E 2026 (Rs mn)           | FY25   | FY26   | FY27E  | FY28E  | FY29E  |
| Interest Income            | 38,426 | 41,739 | 46,161 | 52,631 | 60,845 |
| Interest Expense           | 24,882 | 25,632 | 28,664 | 32,802 | 37,922 |
| Net interest income        | 13,544 | 16,106 | 17,498 | 19,829 | 22,923 |
| NII growth (%)             | 7.6    | 18.9   | 8.6    | 13.3   | 15.6   |
| Non interest income        | 370    | 444    | 521    | 600    | 694    |
| Total income               | 13,915 | 16,550 | 18,019 | 20,429 | 23,617 |
| Operating expenses         | 2,382  | 3,118  | 3,651  | 4,085  | 4,644  |
| PPOP                       | 11,532 | 13,432 | 14,368 | 16,344 | 18,973 |
| PPOP growth (%)            | 7.2    | 16.5   | 7.0    | 13.8   | 16.1   |
| Provisions & contingencies | 758    | 396    | 544    | 712    | 861    |
| PBT                        | 10,775 | 13,036 | 13,823 | 15,632 | 18,112 |
| Extraordinary items        | -      | -      | -      | -      | -      |
| Tax expense                | 2,203  | 2,178  | 2,765  | 3,126  | 3,622  |
| Minority interest          | -      | -      | -      | -      | -      |
| Income from JV/Associates  | -      | -      | -      | -      | -      |
| Reported PAT               | 8,572  | 10,858 | 11,059 | 12,506 | 14,489 |
| PAT growth (%)             | 14.2   | 26.7   | 1.9    | 13.1   | 15.9   |
| Adjusted PAT               | 8,572  | 10,858 | 11,059 | 12,506 | 14,489 |
| Diluted EPS (Rs)           | 64.7   | 81.5   | 83.0   | 93.9   | 108.8  |
| Diluted EPS growth (%)     | 14.8   | 26.0   | 1.9    | 13.1   | 15.9   |
| DPS (Rs)                   | 12.0   | 15.0   | 12.5   | 14.1   | 16.3   |
| Dividend payout (%)        | 18.5   | 18.4   | 15.0   | 15.0   | 15.0   |
| Effective tax rate (%)     | 20.4   | 16.7   | 20.0   | 20.0   | 20.0   |
| Net interest margins (%)   | 3.7    | 4.0    | 3.9    | 3.8    | 3.8    |
| Cost-income ratio (%)      | 17.1   | 18.8   | 20.3   | 20.0   | 19.7   |
| PAT/PPOP (%)               | 74.3   | 80.8   | 77.0   | 76.5   | 76.4   |
| Shares outstanding (mn)    | 133.2  | 133.2  | 133.2  | 133.2  | 133.2  |

Source: Company, Emkay Research

| Balance Sheet              |         |         |         |         |         |
|----------------------------|---------|---------|---------|---------|---------|
| Y/E 2026 (Rs mn)           | FY25    | FY26    | FY27E   | FY28E   | FY29E   |
| Share capital              | 266     | 266     | 266     | 266     | 266     |
| Reserves & surplus         | 50,409  | 59,538  | 68,937  | 81,443  | 95,933  |
| Net worth                  | 50,675  | 59,804  | 69,204  | 81,710  | 96,199  |
| Borrowings                 | 348,639 | 380,422 | 436,380 | 503,518 | 583,064 |
| Other liabilities & prov.  | 10,360  | 3,584   | 1,542   | 1,665   | 1,798   |
| Total liabilities & equity | 409,673 | 443,811 | 507,126 | 586,893 | 681,062 |
| Net loans                  | 376,964 | 416,472 | 480,407 | 554,366 | 641,945 |
| Investments                | 23,740  | 21,430  | 17,749  | 23,476  | 27,242  |
| Cash, other balances       | 3,076   | 3,045   | 3,479   | 4,027   | 4,673   |
| Interest earning assets    | 403,781 | 440,947 | 501,636 | 581,868 | 673,860 |
| Fixed assets               | 503     | 499     | 549     | 603     | 664     |
| Other assets               | 5,389   | 2,365   | 4,942   | 4,421   | 6,538   |
| Total assets               | 409,673 | 443,811 | 507,126 | 586,893 | 681,062 |
| BVPS (Rs)                  | 380.6   | 449.1   | 519.7   | 613.6   | 722.4   |
| Adj. BVPS (INR)            | 380.6   | 449.1   | 519.7   | 613.6   | 722.4   |
| Gross loans                | 382,170 | 422,090 | 484,867 | 559,465 | 647,849 |
| Total AUM                  | 382,170 | 422,090 | 484,867 | 559,465 | 647,849 |
| On balance sheet           | 382,170 | 422,090 | 484,867 | 559,465 | 647,849 |
| Off balance sheet          | 0       | 0       | 0       | 0       | 0       |
| Disbursements              | 85,680  | 105,330 | 128,503 | 155,488 | 186,586 |
| Disbursements growth (%)   | 5.6     | 22.9    | 22.0    | 21.0    | 20.0    |
| Loan growth (%)            | 9.1     | 10.5    | 15.4    | 15.4    | 15.8    |
| AUM growth (%)             | 8.3     | 10.4    | 14.9    | 15.4    | 15.8    |
| Borrowings growth (%)      | 10.5    | 9.1     | 14.7    | 15.4    | 15.8    |
| Book value growth (%)      | 16.7    | 18.0    | 15.7    | 18.1    | 17.7    |

Source: Company, Emkay Research

| Asset quality and other metrics |       |       |       |       |       |
|---------------------------------|-------|-------|-------|-------|-------|
| Y/E 2026 (Rs mn)                | FY25  | FY26  | FY27E | FY28E | FY29E |
| Asset quality                   |       |       |       |       |       |
| GNPL - Stage 3                  | 3,330 | 3,570 | 4,101 | 4,732 | 5,479 |
| NNPL - Stage 3                  | 1,740 | 1,470 | 1,804 | 2,129 | 2,466 |
| GNPL ratio - Stage 3 (%)        | 0.9   | 0.8   | 0.8   | 0.8   | 0.8   |
| NNPL ratio - Stage 3 (%)        | 0.5   | 0.4   | 0.4   | 0.4   | 0.4   |
| ECL coverage - Stage 3 (%)      | 47.7  | 58.8  | 56.0  | 55.0  | 55.0  |
| ECL coverage - 1 & 2 (%)        | 0.5   | 0.5   | 0.5   | 0.5   | 0.5   |
| Gross slippage - Stage 3        | -     | -     | -     | -     | -     |
| Gross slippage ratio (%)        | -     | -     | -     | -     | -     |
| Write-off ratio (%)             | -     | -     | -     | -     | -     |
| Total credit costs (%)          | 0.9   | 0.9   | 0.9   | 0.9   | 0.9   |
| NNPA to networth (%)            | 3.4   | 2.5   | 2.6   | 2.6   | 2.6   |
| Capital adequacy                |       |       |       |       |       |
| Total CAR (%)                   | 25.1  | 21.5  | 21.0  | 20.5  | 20.2  |
| Tier-1 (%)                      | -     | -     | -     | -     | -     |
| Miscellaneous                   |       |       |       |       |       |
| Total income growth (%)         | 7.6   | 18.9  | 8.9   | 13.4  | 15.6  |
| Opex growth (%)                 | 9.7   | 30.9  | 17.1  | 11.9  | 13.7  |
| PPOP margin (%)                 | 3.1   | 3.3   | 3.2   | 3.1   | 3.1   |
| Credit costs-to-PPOP (%)        | 6.6   | 2.9   | 3.8   | 4.4   | 4.5   |
| Loan-to-Assets (%)              | 92.0  | 93.8  | 94.7  | 94.5  | 94.3  |
| Yield on loans (%)              | 10.5  | 10.4  | 10.2  | 10.1  | 10.1  |
| Cost of funds (%)               | 7.5   | 7.0   | 7.0   | 7.0   | 7.0   |
| Spread (%)                      | 3.0   | 3.4   | 3.2   | 3.1   | 3.1   |

Source: Company, Emkay Research

| Valuations and key Ratios |      |      |       |       |       |
|---------------------------|------|------|-------|-------|-------|
| Y/E 2026                  | FY25 | FY26 | FY27E | FY28E | FY29E |
| P/E (x)                   | 13.2 | 10.5 | 10.3  | 9.1   | 7.9   |
| P/B (x)                   | 2.3  | 1.9  | 1.6   | 1.4   | 1.2   |
| P/ABV (x)                 | 2.3  | 1.9  | 1.6   | 1.4   | 1.2   |
| P/PPOP (x)                | 0.0  | 0.0  | 0.0   | 0.0   | 0.0   |
| Dividend yield (%)        | 1.4  | 1.7  | 1.5   | 1.6   | 1.9   |
| Dupont-RoE split (%)      |      |      |       |       |       |
| NII/avg AUM               | 3.7  | 4.0  | 3.9   | 3.8   | 3.8   |
| Other income              | 0.1  | 0.1  | 0.1   | 0.1   | 0.1   |
| Securitization income     | -    | -    | -     | -     | -     |
| Opex                      | 0.6  | 0.8  | 0.8   | 0.8   | 0.8   |
| Employee expense          | -    | -    | -     | -     | -     |
| PPOP                      | 3.1  | 3.3  | 3.2   | 3.1   | 3.1   |
| Provisions                | 0.2  | 0.1  | 0.1   | 0.1   | 0.1   |
| Tax expense               | 0.6  | 0.5  | 0.6   | 0.6   | 0.6   |
| RoAUM (%)                 | 2.3  | 2.7  | 2.4   | 2.4   | 2.4   |
| Leverage ratio (x)        | 7.8  | 7.3  | 7.0   | 6.9   | 6.8   |
| RoE (%)                   | 18.2 | 19.7 | 17.1  | 16.6  | 16.3  |

| Quarterly data |        |        |        |        |        |
|----------------|--------|--------|--------|--------|--------|
| Rs mn, Y/E Mar | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
| NII            | 3,628  | 4,046  | 4,210  | 4,223  | 4,276  |
| NIM (%)        | 3.8    | 4.1    | 4.2    | 4.1    | 4.0    |
| PPOP           | 3,039  | 3,346  | 3,511  | 3,535  | 3,516  |
| PAT            | 2,239  | 2,514  | 2,648  | 3,457  | 2,678  |
| EPS (Rs)       | 16.81  | 18.88  | 19.89  | 25.90  | 20.11  |

Source: Company, Emkay Research


This report is intended for Team White Marque Solutions (team.emkay@whitemarqueresolutions)

RECOMMENDATION HISTORY - DETAILS

| Date      | Closing Price (Rs) | TP (Rs) | Rating | Analyst       |
|-----------|--------------------|---------|--------|---------------|
| 17-Jul-26 | 889                | 1,000   | Add    | Avinash Singh |
| 17-Jul-26 | 889                | 1,000   | Add    | Avinash Singh |

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)

**GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com).

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

This report is intended for Team White Marque Solutions ([team.emkay@whitemarquessolutions.com](mailto:team.emkay@whitemarquessolutions.com))

**RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons<sup>1</sup> may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of July 20, 2026
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

**Disclosure of previous investment recommendation produced:**

- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of July 20, 2026
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the July 20, 2026
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

**Emkay Rating Distribution**

| Ratings       | Expected Return within the next 12-18 months. |
|---------------|-----------------------------------------------|
| <b>BUY</b>    | >15% upside                                   |
| <b>ADD</b>    | 5-15% upside                                  |
| <b>REDUCE</b> | 5% upside to 15% downside                     |
| <b>SELL</b>   | >15% downside                                 |

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for Team White Marque Solutions (team.emkay@whitemarquessolutions)

**OTHER DISCLAIMERS AND DISCLOSURES:****Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

This report is intended for Team White Marque Solutions ([team.emkay@whitemarquesolutions](mailto:team.emkay@whitemarquesolutions))